Evidence for a two-phonon octupole vibrational state in208Pb

Collective properties of206,208Pb have been investigated with gamma-ray spectroscopy using nuclear and electromagnetic excitation by208Pb projectiles. From the measurement of particle-particle-γ and particle-particle-γ γ coincidences a new energy level in208Pb at 5.683 MeV was observed and the data suggest an interpretation as a 2-phonon octupole vibrational state with spin 4+ or 6+. For this state one finds the same dynamical deformation parameterβ3 as for the first-excited collective 3− state. The results are compared to predictions of models which consider, in particular, the aspects of the quadrupole interaction and the interaction of the 2-particle pairing vibration with the 2-phonon o…

Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure

The hemodynamic and anti-ischemic effects of nitroglycerin (GTN) are rapidly blunted as a result of the development of nitrate tolerance. Hydralazine has been shown to prevent tolerance in experimental and clinical studies, all of which may be at least in part secondary to antioxidant properties of this compound. The antioxidant effects of hydralazine were tested in cell free systems, cultured smooth muscle cells, isolated mitochondria, and isolated vessels. Inhibitory effects on the formation of superoxide and/or peroxynitrite formation were tested using lucigenin and L-012 enhanced chemiluminescence as well as DHE-fluorescence. The peroxynitrite scavenging properties were also assessed by…

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

469: Prospective, randomized, multicenter trial comparing conversion to a CNI-free regimen (MMF & sirolimus) vs. a CNI-reduced, MMF-based immunosuppression to improve renal function in late cardiac transplant recipients